EP3805218A1 - Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) - Google Patents

Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) Download PDF

Info

Publication number: EP3805218A1
Authority: EP; European Patent Office
Prior art keywords: optionally substituted; compound; mmol; bond; alkyl
Prior art date: 2014-04-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP20187913.7A

Other languages

German (de)

English (en)

Inventor

Jason J. MARINEAU

Kevin Sprott

Darby Schmidt

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Syros Pharmaceuticals Inc

Original Assignee

Syros Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-05

Filing date

2015-04-03

Publication date

2021-04-14

2015-04-03 Application filed by Syros Pharmaceuticals Inc filed Critical Syros Pharmaceuticals Inc

2021-04-14 Publication of EP3805218A1 publication Critical patent/EP3805218A1/fr

Status Withdrawn legal-status Critical Current

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

CDK7 cyclin-dependent kinase family play critical regulatory roles in proliferation.
CDK7 has consolidated kinase activities, regulating both the cell cycle and transcription.
CDK7 exists as a heterotrimeric complex and is believed to function as a CDK1/2-activating kinase (CAK), whereby phosphorylation of conserved residues in CDK1/2 by CDK7 is required for full catalytic CDK activity and cell cycle progression.
CAK CDK1/2-activating kinase
CDK7 forms the kinase core of the RNA polymerase (RNAP) II general transcription factor complex and is charged with phosphorylating the C-terminal domain (CTD) of RNAP II, a requisite step in gene transcriptional initiation
RNAP RNA polymerase
CTD C-terminal domain
RNAP II CTD phosphorylation has been shown to preferentially affect proteins with short half-lives, including those of the anti-apoptotic BCL-2 family. Cancer cells have demonstrated ability to circumvent pro-cell death signaling through upregulation of BCL-2 family members. Therefore, inhibition of human CDK7 kinase activity is likely to result in anti-proliferative activity.
FIG. 1 is a table of exemplary compounds of the invention.
the present invention provides inhibitors of one or more of the family of CDK proteins.
the present invention further provides CDK7 inhibitors, in particular selective CDK7 inhibitors of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof.
the present invention further provides methods of using the compounds of the invention, and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof, to study the inhibition of CDK7 and CDK12 and/or CDK13 as therapeutics for the prevention and/or treatment of diseases associated with overexpression and/or aberrant activity of CDK7 and/or CDK12 and/or CDK13.
the inventive compounds are used for the prevention and/or treatment of proliferative diseases (e.g ., cancers (e.g ., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
proliferative diseases e.g ., cancers (e.g ., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases.
the present invention provides a compound described herein, such as of Formula (I): or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein G, R 2 , Q, R 3 , Z, and R 4 and subvariables thereof are as defined herein.
the present invention provides pharmaceutical compositions comprising a compound described herein, such as of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof, and optionally a pharmaceutically acceptable excipient.
the pharmaceutical compositions described herein include a therapeutically effective amount of a compound described herein, such as of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof.
the pharmaceutical composition may be useful for treating and/or preventing a proliferative or infectious disease.
the present invention provides methods for treating and/or preventing proliferative diseases.
proliferative diseases include cancer (e.g ., leukemia, melanoma, multiple myeloma), benign neoplasm, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases.
the present invention provides methods for treating and/or preventing an infectious disease (e.g ., a viral infection).
the present invention provides methods of down-regulating the expression of CDK7 in a biological sample or subject.
Another aspect of the invention relates to methods of inhibiting the activity of CDK7 in a biological sample or subject.
the present invention also provides methods of inhibiting cell growth in a biological sample or subject.
the present invention provides methods of inducing apoptosis of a cell in a biological sample or a subject.
the present invention provides compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof, for use in the treatment of a proliferative disease in a subject.
the present invention provides compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof, for use in the treatment or prevention of an infectious disease in a subject.
the infectious disease is a viral infection.
kits comprising a container with a compound described herein, such as of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof, or a pharmaceutical composition thereof.
the kits described herein further include instructions for administering the compound described herein, such as of Formula (I), or the pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof, or the pharmaceutical composition thereof.
the present invention provides methods of inhibiting other CDKs, specifically CDK12 and/or CDK13, with a compound described herein, such as of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer, or a pharmaceutical composition thereof.
structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
a particular enantiomer may, in some embodiments be provided substantially free of the corresponding enantiomer, and may also be referred to as "optically enriched.”
“Optically enriched,” as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%, or 99% by weight of a preferred enantiomer.
Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses.
HPLC high pressure liquid chromatography
Jacques et al. Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981 ); Wilen, et al., Tetrahedron 33:2725 (1977 ); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962 ); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972 ).
aliphatic or "aliphatic group”, as used herein, denotes a hydrocarbon moiety that may be straight-chain (i.e., unbranched), branched, or cyclic (including fused, bridging, and spiro-fused polycyclic) and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, aliphatic groups contain 1-6 carbon atoms. In some embodiments, aliphatic groups contain 1-4 carbon atoms, and in yet other embodiments aliphatic groups contain 1-3 carbon atoms.
Suitable aliphatic groups include, but are not limited to, linear or branched, alkyl, alkenyl, and alkynyl groups, and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl. Aliphatic groups may be optionally substituted, e.g., as described herein.
alkyl refers to a monovalent saturated, straight- or branched-chain hydrocarbon such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C 1 -C 12 alkyl, C 1 -C 10 alkyl, and C 1 -C 6 alkyl, respectively. Alkyl groups may be optionally substituted, e.g., as described herein.
alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec-hexyl, and the like.
An alkyl may be optionally substituted, e.g., as described herein.
alkenyl and alkynyl are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.
alkylene refers to the diradical of an alkyl group.
alkenylene and “alkynylene” refer to the diradicals of an alkenyl and an alkynyl group, respectively.
methylene unit refers to a divalent -CH 2 - group present in an alkyl, alkenyl, alkynyl, alkylene, alkenylene, or alkynylene moiety.
carrier means a monocyclic, or fused, spiro-fused, and/or bridged bicyclic or polycyclic hydrocarbon ring system, wherein each ring is either completely saturated or contains one or more units of unsaturation, but where no ring is aromatic.
carbocyclyl refers to a radical of a carbocyclic ring system.
Representative carbocyclyl groups include cycloalkyl groups (e.g., cyclopentyl, cyclobutyl, cyclopentyl, cyclohexyl and the like), and cycloalkenyl groups (e.g., cyclopentenyl, cyclohexenyl, cyclopentadienyl, and the like).
a carbocyclyl may be optionally substituted, e.g., as described herein.
aromatic ring system refers to a monocyclic, bicyclic or polycyclic hydrocarbon ring system, wherein at least one ring is aromatic.
aryl refers to a radical of an aromatic ring system.
Representative aryl groups include fully aromatic ring systems, such as phenyl, naphthyl, and anthracenyl, and ring systems where an aromatic carbon ring is fused to one or more non-aromatic carbon rings, such as indanyl, phthalimidyl, naphthimidyl, or tetrahydronaphthyl, and the like.
An aryl may be optionally substituted, e.g., as described herein.
heteromatic ring system refers to monocyclic, bicyclic or polycyclic ring system wherein at least one ring is both aromatic and comprises a heteroatom; and wherein no other rings are heterocyclyl (as defined below).
a ring which is aromatic and comprises a heteroatom contains 1, 2, 3, or 4 independently selected ring heteroatoms in such ring.
heteroaryl refers to a radical of a heteroaromatic ring system.
Representative heteroaryl groups include ring systems where (i) each ring comprises a heteroatom and is aromatic, e.g., imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrrolyl, furanyl, thiophenyl pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl; (ii) each ring is aromatic or carbocyclyl, at least one aromatic ring comprises a heteroatom and at least one other ring is a hydrocarbon ring or e.g., indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimid
the heteroaryl is a monocyclic or bicyclic ring, wherein each of said rings contains 5 or 6 ring atoms where 1, 2, 3, or 4 of said ring atoms are a heteroatom independently selected from N, O, and S.
a heteroaryl may be optionally substituted, e.g., as described herein.
heterocyclic ring system refers to monocyclic, or fused, spiro-fused, and/or bridged bicyclic and polycyclic ring systems where at least one ring is saturated or partially unsaturated (but not aromatic) and comprises a heteroatom.
a heterocyclic ring system can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
heterocyclyl refers to a radical of a heterocyclic ring system.
Representative heterocyclyls include ring systems in which (i) every ring is non-aromatic and at least one ring comprises a heteroatom, e.g., tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl; (ii) at least one ring is non-aromatic and comprises a heteroatom and at least one other ring is an aromatic carbon ring, e.g., 1,2,3,4-tetrahydroquinolinyl, 1,2,
the heterocyclyl is a monocyclic or bicyclic ring, wherein each of said rings contains 3-7 ring atoms where 1, 2, 3, or 4 of said ring atoms are a heteroatom independently selected from N, O, and S.
a heterocyclyl may be optionally substituted, e.g., as described herein.
saturated heterocyclyl refers to a radical of heterocyclic ring system wherein every ring is saturated, e.g., tetrahydrofuran, tetrahydro-2H-pyran, pyrrolidine, piperidine and piperazine.
Partially unsaturated refers to a group that includes at least one double or triple bond.
a “partially unsaturated” ring system is further intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic groups (e.g., aryl or heteroaryl groups) as herein defined.
aromatic groups e.g., aryl or heteroaryl groups
saturated refers to a group that does not contain a double or triple bond, i.e., contains all single bonds.
compounds of the invention may contain "optionally substituted” moieties.
substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position.
Combinations of substituents envisioned under this invention are preferably those that result in the formation of stable or chemically feasible compounds.
stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
Suitable monovalent substituents on R ⁇ are independently deuterium, halogen, -(CH 2 ) 0-2 R • , -(haloR • ), -(CH 2 ) 0-2 OH, -(CH 2 ) 0-2 OR • , -(CH 2 ) 0-2 CH(OR • ) 2 ; -O(haloR • ), -CN, -N 3 , -(CH 2 ) 0-2 C(O)R • , -(CH 2 ) 0-2 C(O)OH, -(CH 2 ) 0-2 C(O)OR • , -(CH 2 ) 0-2 SR • , -(CH 2 ) 0-2 SH, -(CH 2 ) 0-2 NH 2 , -(CH 2 ) 0-2 NHR • , -(CH 2 ) 0-2
Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -O(CR* 2 ) 2-3 O-, wherein each independent occurrence of R* is selected from hydrogen, C 1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on the aliphatic group of R* include deuterium, halogen, -R*, -(haloR • ), -OH, -OR • , -O(haloR • ), -CN, -C(O)OH, -C(O)OR • , -NH 2 , -NHR • , -NR • 2 , or -NO 2 , wherein each R • is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C 1-4 aliphatic, -CH 2 Ph, -O(CH 2 ) 0-1 Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R ⁇ , -NR ⁇ 2 , -C(O)R ⁇ , -C(O)OR ⁇ , -C(O)C(O)R ⁇ , -C(O)CH 2 C(O)R ⁇ , -S(O) 2 R ⁇ , -S(O) 2 NR ⁇ 2 , -C(S)NR ⁇ 2 , -C(NH)NR ⁇ 2 , or -N(R ⁇ )S(O) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, C 1-6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrence
Suitable substituents on the aliphatic group of R ⁇ are independently deuterium, halogen, -R • , -(haloR • ), -OH, -OR • , -O(haloR • ), -CN, -C(O)OH, -C(O)OR • , -NH 2 , -NHR • , -NR • 2 , or -NO 2 , wherein each R • is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C 1-4 aliphatic, -CH 2 Ph, -O(CH 2 ) 0-1 Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
Halo or halogen refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).
the moieties, -O-, -S-, and -NR X - are included in this definition because in each case they represent a C 1 alkylene (i.e., methylene) replaced with -O-, -S-, or -NR X -, respectively.
leaving group is given its ordinary meaning in the art of synthetic organic chemistry and refers to an atom or a group capable of being displaced by a nucleophile.
suitable leaving groups include, but are not limited to, halogen (such as F, Cl, Br, or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g., acetoxy), arylcarbonyloxy, aryloxy, methoxy, N,O -dimethylhydroxylamino, pixyl, and haloformates.
the leaving group is a sulfonic acid ester, such as toluenesulfonate (tosylate, -OTs), methanesulfonate (mesylate, - OMs), p-bromobenzenesulfonyloxy (brosylate, -OBs), or trifluoromethanesulfonate (triflate, - OTf).
the leaving group is a brosylate, such as p-bromobenzenesulfonyloxy.
the leaving group is a nosylate, such as 2-nitrobenzenesulfonyloxy.
the leaving group is a sulfonate-containing group. In some embodiments, the leaving group is a tosylate group.
the leaving group may also be a phosphineoxide (e.g., formed during a Mitsunobu reaction) or an internal leaving group such as an epoxide or cyclic sulfate.
Other non-limiting examples of leaving groups are water, ammonia, alcohols, ether moieties, thioether moieties, zinc halides, magnesium moieties, diazonium salts, and copper moieties.
the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19 , incorporated herein by reference.
Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid
organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 - salts.
Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
solvate refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association may include hydrogen bonding.
solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, and the like.
the compounds described herein, such as of Formula (I) may be prepared, e.g., in crystalline form, and may be solvated.
Suitable solvates include pharmaceutically acceptable solvates and further include both stoichiometric solvates and non-stoichiometric solvates.
the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the crystal lattice of a crystalline solid.
“Solvate” encompasses both solution-phase and isolable solvates.
Representative solvates include hydrates, ethanolates, and methanolates.
hydrate refers to a compound which is associated with water.
the number of the water molecules contained in a hydrate of a compound is in a definite ratio to the number of the compound molecules in the hydrate. Therefore, a hydrate of a compound may be represented, for example, by the general formula R ⁇ x H 2 O, wherein R is the compound and wherein x is a number greater than 0.
a given compound may form more than one type of hydrates, including, e.g., monohydrates (x is 1), lower hydrates (x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R ⁇ 0.5 H 2 O)), and polyhydrates (x is a number greater than 1, e.g., dihydrates (R ⁇ 2 H 2 O) and hexahydrates (R ⁇ 6 H 2 O)).
monohydrates x is 1
lower hydrates x is a number greater than 0 and smaller than 1, e.g., hemihydrates (R ⁇ 0.5 H 2 O)
polyhydrates x is a number greater than 1, e.g., dihydrates (R ⁇ 2 H 2 O) and hexahydrates (R ⁇ 6 H 2 O)
tautomers refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of ⁇ electrons and an atom (usually H). For example, enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base. Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane, that are likewise formed by treatment with acid or base.
Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”.
enantiomers When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible.
An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively).
a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".
a "subject" to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject ( e.g ., young adult, middle-aged adult, or senior adult)) and/or other non-human animals, for example, mammals (e.g., primates ( e.g., cynomolgus monkeys, rhesus monkeys); commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats, and/or dogs) and birds ( e.g ., commercially relevant birds such as chickens, ducks, geese, and/or turkeys).
the animal is a mammal.
the animal may be a male or female and at any stage of development.
a non-human animal may be a transgenic animal.
administer refers to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing an inventive compound, or a pharmaceutical composition thereof.
treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a "pathological condition” (e.g ., a disease, disorder, or condition, or one or more signs or symptoms thereof) described herein.
pathological condition e.g ., a disease, disorder, or condition, or one or more signs or symptoms thereof
“treatment,” “treat,” and “treating” require that signs or symptoms of the disease disorder or condition have developed or have been observed.
treatment may be administered in the absence of signs or symptoms of the disease or condition.
treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g ., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example, to delay or prevent recurrence.
condition As used herein, the terms “condition,” “disease,” and “disorder” are used interchangeably.
an "effective amount" of a compound described herein, such as of Formula (I) refers to an amount sufficient to elicit the desired biological response, i.e., treating the condition.
the effective amount of a compound described herein, such as of Formula (I) may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject.
An effective amount encompasses therapeutic and prophylactic treatment.
an effective amount of an inventive compound may reduce the tumor burden or stop the growth or spread of a tumor.
a “therapeutically effective amount” of a compound described herein, such as of Formula (I) is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to delay or minimize one or more symptoms associated with the condition.
a therapeutically effective amount is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or to minimize one or more symptoms associated with the condition.
a therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment of the condition.
the term "therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of the condition, or enhances the therapeutic efficacy of another therapeutic agent.
a “prophylactically effective amount” of a compound described herein, such as of Formula (I) is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition or prevent its recurrence.
a prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, which provides a prophylactic benefit in the prevention of the condition.
the term “prophylactically effective amount” can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.
proliferative disease refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells ( Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990 ).
a proliferative disease may be associated with: 1) the pathological proliferation of normally quiescent cells; 2) the pathological migration of cells from their normal location ( e.g ., metastasis of neoplastic cells); 3) the pathological expression of proteolytic enzymes such as the matrix metalloproteinases (e.g ., collagenases, gelatinases, and elastases); or 4) the pathological angiogenesis as in proliferative retinopathy and tumor metastasis.
Exemplary proliferative diseases include cancers ( i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases.
neoplasm and “tumor” are used herein interchangeably and refer to an abnormal mass of tissue wherein the growth of the mass surpasses and is not coordinated with the growth of a normal tissue.
a neoplasm or tumor may be “benign” or “malignant,” depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), rate of growth, local invasion, and metastasis.
a “benign neoplasm” is generally well differentiated, has characteristically slower growth than a malignant neoplasm, and remains localized to the site of origin.
a benign neoplasm does not have the capacity to infiltrate, invade, or metastasize to distant sites.
Exemplary benign neoplasms include, but are not limited to, lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheic keratoses, lentigos, and sebaceous hyperplasias.
certain "benign" tumors may later give rise to malignant neoplasms, which may result from additional genetic changes in a subpopulation of the tumor's neoplastic cells, and these tumors are referred to as "pre-malignant neoplasms.”
An exemplary pre-malignant neoplasm is a teratoma.
a malignant neoplasm is generally poorly differentiated (anaplasia) and has characteristically rapid growth accompanied by progressive infiltration, invasion, and destruction of the surrounding tissue. Furthermore, a malignant neoplasm generally has the capacity to metastasize to distant sites.
cancer refers to a malignant neoplasm ( Stedman's Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins: Philadelphia, 1990 ).
exemplary cancers include, but are not limited to, acoustic neuroma; adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma ( e.g.
lymphangiosarcoma lymphangioendotheliosarcoma, hemangiosarcoma
appendix cancer benign monoclonal gammopathy; biliary cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g ., adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast); brain cancer ( e.g., meningioma, glioblastomas, glioma ( e.g ., astrocytoma, oligodendroglioma), medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer ( e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; craniopharyngioma; colorectal cancer ( e.g., colon cancer, rectal cancer, colorectal cancer ( e.
liver cancer e.g., hepatocellular cancer (HCC), malignant hepatoma
lung cancer e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung
leiomyosarcoma LMS
mastocytosis e.g ., systemic mastocytosis
muscle cancer myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorder (MPD) (e.g ., polycythemia vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a.
myelofibrosis MF
chronic idiopathic myelofibrosis chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)
neuroblastoma e.g ., neurofibromatosis (NF) type 1 or type 2, schwannomatosis
neuroendocrine cancer e.g ., gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor
osteosarcoma e.g ., bone cancer
ovarian cancer e.g ., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma
papillary adenocarcinoma pancreatic cancer
pancreatic adenocarcinoma intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors
penile cancer e.g ., Paget's disease of the penis and scrotum
pinealoma primitive neuroectodermal tumor (PNT); plasma cell neoplasia; paraneoplastic syndromes; intraepithelial neoplasms
prostate cancer e.g ., prostate adenocarcinoma
rectal cancer rhabdomyosarcoma; salivary gland cancer; skin cancer ( e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, mal
angiogenesis refers to the formation and the growth of new blood vessels. Normal angiogenesis occurs in the healthy body of a subject for healing wounds and for restoring blood flow to tissues after injury.
the healthy body controls angiogenesis through a number of means, e.g ., angiogenesis-stimulating growth factors and angiogenesis inhibitors.
Many disease states such as cancer, diabetic blindness, age-related macular degeneration, rheumatoid arthritis, and psoriasis, are characterized by abnormal ( i.e., increased or excessive) angiogenesis.
Abnormal angiogenesis refers to angiogenesis greater than that in a normal body, especially angiogenesis in an adult not related to normal angiogenesis (e.g ., menstruation or wound healing).
Abnormal angiogenesis can provide new blood vessels that feed diseased tissues and/or destroy normal tissues, and in the case of cancer, the new vessels can allow tumor cells to escape into the circulation and lodge in other organs (tumor metastases).
an "inflammatory disease” refers to a disease caused by, resulting from, or resulting in inflammation.
the term “inflammatory disease” may also refer to a dysregulated inflammatory reaction that causes an exaggerated response by macrophages, granulocytes, and/or T-lymphocytes leading to abnormal tissue damage and/or cell death.
An inflammatory disease can be either an acute or chronic inflammatory condition and can result from infections or non-infectious causes.
Inflammatory diseases include, without limitation, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, arthrosteitis, rheumatoid arthritis, inflammatory arthritis, Sjogren's syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (e.g.
an "autoimmune disease” refers to a disease arising from an inappropriate immune response of the body of a subject against substances and tissues normally present in the body. In other words, the immune system mistakes some part of the body as a pathogen and attacks its own cells. This may be restricted to certain organs (e.g., in autoimmune thyroiditis) or involve a particular tissue in different places (e.g ., Goodpasture's disease which may affect the basement membrane in both the lung and kidney).
the treatment of autoimmune diseases is typically with immunosuppression, e.g ., medications which decrease the immune response.
Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture's syndrome, necrotizing vasculitis, lymphadenitis, peri-arteritis nodosa, systemic lupus erythematosis, rheumatoid, arthritis, psoriatic arthritis, systemic lupus erythematosis, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis/polymyositis, anti-phospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g.
autoinflammatory disease refers to a category of diseases that are similar but different from autoimmune diseases. Autoinflammatory and autoimmune diseases share common characteristics in that both groups of disorders result from the immune system attacking a subject's own tissues and result in increased inflammation. In autoinflammatory diseases, a subject's innate immune system causes inflammation for unknown reasons. The innate immune system reacts even though it has never encountered autoantibodies or antigens in the subject. Autoinflammatory disorders are characterized by intense episodes of inflammation that result in such symptoms as fever, rash, or joint swelling. These diseases also carry the risk of amyloidosis, a potentially fatal buildup of a blood protein in vital organs.
Autoinflammatory diseases include, but are not limited to, familial Mediterranean fever (FMF), neonatal onset multisystem inflammatory disease (NOMID), tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS), deficiency of the interleukin-1 receptor antagonist (DIRA), and Behçet's disease.
FMF familial Mediterranean fever
NOMID neonatal onset multisystem inflammatory disease
TNF tumor necrosis factor
TRAPS tumor necrosis factor receptor-associated periodic syndrome
DIRA deficiency of the interleukin-1 receptor antagonist
Behçet's disease Behçet's disease.
tissue samples such as tissue sections and needle biopsies of a tissue
cell samples e.g ., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); samples of whole organisms (such as samples of yeasts or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating the components thereof by centrifugation or otherwise).
Other examples of biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucus, tears, sweat, pus, biopsied tissue (e.g.
Bio samples also include those biological samples that are transgenic, such as transgenic oocyte, sperm cell, blastocyst, embryo, fetus, donor cell, or cell nucleus.
each R 1 is independently selected from hydrogen, halogen, heterocyclyl, aryl, heteroaryl, optionally substituted C 1 -C 6 alkyl, carbocyclyl, -OR a , -NR b R c , -C(O)R a , -C(O)NR b R c , -S(O) x R a , and -S(O) x NR b R c ;
R A6 is hydrogen, halogen, heterocyclyl, C 1 -C 6 alkyl, carbocyclyl, -OR a , -NR b R c , -C(O)R a , -C(O)NR b R c , -S(O) x R a , and -S(O) x NR b R c ;
R A6 is hydrogen, halogen, heterocyclyl, C 1 -C 6 alkyl, carbo
the compound of formula (I) is a compound having the structural formula (IIb):
the compound of formula (IIb) is the compound:
the compound of formula (I) is a compound having the structural formula (IIc):
the compound of formula (I) is a compound having the structural formula (IId): wherein V is hydrogen, halogen, heterocyclyl, aryl, heteroaryl, C 1 -C 6 alkyl, carbocyclyl, -OR a ,-NR b R c , -S(O) x R a , -S(O) x NR b R c ; and W is hydrogen, halogen, heterocyclyl, aryl, heteroaryl, C 1 -C6 alkyl, carbocyclyl, -OR a , -NR b R c , -S(O) x R a , -S(O)xNR b R c .
the compound of formula (IId) is a compound having the structural formula (IIe):
the compound of formula (IId) is a compound having the structural formula (IIf):
the compound of formula (I) is a compound having the structural formula (IIg):
the compound of formula (IIg) is a compound having the structural formula (IIh):
the compound of formula (IIh) is a compound having the structural formula (IIi):
A is optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl
R B is C 1 -C 6 alkyl or halogen
q is 0, 1, 2, or 3.
the compound of formula (IIi) is a compound having the structural formula (IIj):
R 2B is a bond or optionally substituted -CH 2 ; and B is optionally substituted divalent aryl, optionally substituted divalent heteroaryl, or optionally substituted divalent heterocyclyl.
the compound of formula (IIj) is the compound
the compound of formula (IIj) is a compound having the structural formula (Ilk):
A is optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl
C is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, or optionally substituted monocyclic heterocyclyl
R B is C 1 -C 6 alkyl or halogen
R 3B is a bond, optionally substituted -NHC(O)-, optionally substituted -CH 2 -, optionally substituted -NH-, optionally substituted -NHCH 2 -, or optionally substituted -CH 2 NH-
each of R E1B and R E2B is independently selected from hydrogen or -CH 2 N(CH 3 ) 2
q is 0, 1, 2, or 3.
the compound of formula (Ilk) is a compound having the structural formula (IIm):
C is optionally substituted monocyclic aryl, optionally substituted monocyclic heteroaryl, or optionally substituted monocyclic heterocyclyl;
R 3B is a bond, optionally substituted -NHC(O)-, optionally substituted -CH 2 -, optionally substituted -NH-, optionally substituted -NHCH 2 -, or optionally substituted -CH 2 NH-; and each of R E1B and R E2B is independently selected from hydrogen or -CH 2 N(CH 3 ) 2 .
the compound of formula (IIm) is the compound: or
the compound of formula (I) is a compound having the structural formula (IIIa):
the compound of formula (IIIa) is a compound having the structural formula (IIIb):
the compound of formula (IIIb) is a compound having the structural formula (IIIc):
the compound of formula (IIIc) is the compound:
the compound of formula (IIIc) is a compound having the structural formula (IIId): wherein R 3C is a bond, optionally substituted -CH 2 -, optionally substituted -NH-, -C(O), -N(CH 3 )-, or optionally substituted -CH(CH 3 )-; and D is optionally substituted monocyclic or bicyclic aryl or heteroaryl.
the compound of formula (IIId) is the compound: or
the compound of formula (IIId) is a compound having the structural formula (IIIe): wherein each of R E1C and R E2C is independently selected from hydrogen or -CH 2 N(CH 3 ) 2 .
the compound of formula (IIIe) is the compound: or
the compound of formula (I) is a compound having the structural formula (IVa):
the compound of formula (IVa) is a compound having the structural formula (IVb):
the compound of formula (I) is a compound having the structural formula (Va):
the compound of formula (Va) is a compound having the structural formula (VIa):
the compound of formula (I) is a compound having the structural formula (VIIa):
the compound of formula (I) is a compound having the structural formula (VIIIa):
the compound of formula (I) is a compound having the structural formula (IXa):
R 2 is a bond, an optionally substituted C 1 -C 4 alkylene or an optionally substituted C 2 -C 4 alkenylene or alkynylene, wherein one or more methylene units of the alkylene, alkenylene or alkynylene are optionally and independently replaced with -O-, -S-, -C(O)-, or -N(R 6 )-, wherein R 6 is hydrogen or a C 1 -C 6 alkyl chain. In some embodiments, R 6 does not comprise AIk 1 .
R 2 is selected from a bond, ⁇ -NH-, ⁇ -C(O), ⁇ -CH 2 -, and ⁇ -NHC(O)-, wherein " ⁇ " represents a portion of R 2 bound to G.
⁇ represents a portion of R 2 bound to G.
Q is selected from a bond, divalent 1,3,4-oxadiazole; divalent 1-oxa-3-azaspiro[4.5]dec-2-ene; divalent cyclohexyl; divalent 4-thia-1,2-diazaspiro[4.5]dec-2-ene; divalent oxazole; divalent phenyl; divalent piperidine and divalent pyrrolidine, wherein Q is optionally substituted with up to three independently selected substituents.
Q is selected from 1,3,4-oxadiazol-2,5-diyl; 1-oxa-3-azaspiro[4.5]dec-2-en-7,2-diyl; 4-fluorocyclohex-1,4-diyl; 4-hydroxycyclohex-1,4-diyl; 4-thia-1,2-diazaspiro[4.5]dec-2-en-7,3-diyl; cyclohex-1,3-diyl; cyclohex-1,4-diyl; oxazol-2,5-diyl; benzene-1,2-diyl; benzene-1,3-diyl; benzene-1,2,3-triyl; piperidin-1,3-diyl; piperidin-1,3-diyl; piperidin-4,1-diyl; piperidin-1,4-diyl; and pyrrolidin-3,1-d
R 3 is selected from a bond, ⁇ -C(O)-(CH 2 ) 3 -, ⁇ -CH 2 CH 2 CH 2 CH 2 CH 2 CH 2 -, ⁇ -C(O)-, ⁇ - C(O)-NH-, ⁇ -NH-C(O)-, ⁇ -NH-C(O)-CF 2 -CH 2 -, ⁇ -CH 2 -, ⁇ -NH-, ⁇ -NH-CH 2 -, ⁇ -CH 2 -NH-, ⁇ -NH-C(O)-CH(CF 3 )-, ⁇ -N(CH 3 )-CH 2 -, ⁇ -NH-C(O)-CH 2 -CH 2 -, ⁇ -CH(CH 3 )-, ⁇ -N(CH 3 )-, and ⁇ -NH-CH 2 -CH(CF 3 )-, wherein " ⁇ " represents a portion of R 3 bound to Q.
Z is selected from a bond, wherein: "1" represents a portion of Z bound to R 3 ; "2" represents a portion of Z bound to R 4 ; each instance of R 5 , if present, is independently selected from deuterium, halogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, -OR D1 , -N(R D1 ) 2 , and -SR D1 , wherein each occurrence of R D1 is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, and optionally substituted aryl, optionally substituted heteroaryl; and m
Z is selected from a bond
Z is selected from a bond, cyclohex-1,4-diyl, piperidin-3,1-diyl, piperidin-4,1-diyl, piperidin-1,2-diyl, piperidin-2,1-diyl, pyridin-2,5-diyl, pyridin-2,4-diyl, bicyclo[1.1.1]pent-1,3-diyl, pyrimidin-2,5-diyl, pyrazol-1,4-diyl, pyrrolidin-2,1-diyl, 4,4-difluoropyrrolidin-2,1-diyl, isoindolin-2,5-diyl, 6-azaspiro[2.5]octan-6,1-diyl, 2,8-diazaspiro[4.5]decan-2,8-diyl, pyrrolidin-3,1-diyl, 5,
the compound of Formula (I) is selected from the group consisting of any one of the compounds in the table in Figure 1 (e.g., Compounds 100-131) and any pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, and isotopically labeled derivatives thereof.
variable in Formula (I) may be selected from a group of chemical moieties
the invention also encompasses as further embodiments and aspects thereof situations where such variable is: a) selected from any subset of chemical moieties in such a group; and b) any single member of such group.
the present invention provides pharmaceutical compositions comprising a compound described herein, such as of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof, as described herein, and optionally a pharmaceutically acceptable excipient.
the pharmaceutical composition of the invention comprises a compound described herein, such as of Formula (I), or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient.
the compound described herein, such as of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof is provided in an effective amount in the pharmaceutical composition.
the effective amount is a therapeutically effective amount.
the effective amount is a prophylactically effective amount.
compositions described herein can be prepared by any method known in the art of pharmacology.
preparatory methods include the steps of bringing the compound described herein, such as of Formula (I) (the "active ingredient”) into association with a carrier and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.
compositions can be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.
a "unit dose" is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient.
the amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
Relative amounts of the active ingredient, the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition of the invention will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered.
the composition may comprise between 0.1% and 100% (w/w) active ingredient.
pharmaceutically acceptable excipient refers to a non-toxic carrier, adjuvant, diluent, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
Pharmaceutically acceptable excipients useful in the manufacture of the pharmaceutical compositions of the invention are any of those that are well known in the art of pharmaceutical formulation and include inert diluents, dispersing and/or granulating agents, surface active agents and/or emulsifiers, disintegrating agents, binding agents, preservatives, buffering agents, lubricating agents, and/or oils.
compositions of the invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
ion exchangers alumina, aluminum stearate, lecithin
serum proteins such as human serum albumin
buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate,
compositions of the present invention may be administered orally, parenterally (including subcutaneous, intramuscular, intravenous and intradermal), by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
provided compounds or compositions are administrable intravenously and/or orally.
parenteral includes subcutaneous, intravenous, intramuscular, intraocular, intravitreal, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intraperitoneal intralesional and intracranial injection or infusion techniques.
the compositions are administered orally, subcutaneously, intraperitoneally or intravenously.
Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
a non-toxic parenterally acceptable diluent or solvent for example as a solution in 1,3-butanediol.
acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
sterile, fixed oils are conventionally employed as a solvent or suspending medium.
compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
carriers commonly used include lactose and corn starch.
Lubricating agents such as magnesium stearate, are also typically added.
useful diluents include lactose and dried cornstarch.
aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
a provided oral formulation is formulated for immediate release or sustained/delayed release.
the composition is suitable for buccal or sublingual administration, including tablets, lozenges and pastilles.
a provided compound can also be in micro-encapsulated form.
compositions of this invention may be administered in the form of suppositories for rectal administration.
Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
compositions may be formulated as micronized suspensions or in an ointment such as petrolatum.
compositions of this invention may also be administered by nasal aerosol or inhalation.
compositions suitable for administration to humans are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with ordinary experimentation.
compositions of the present invention are typically formulated in dosage unit form, e.g., single unit dosage form, for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
the specific therapeutically effective dose level for any particular subject or organism will depend upon a variety of factors including the disease being treated and the severity of the disorder; the activity of the specific active ingredient employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.
the exact amount of a compound required to achieve an effective amount will vary from subject to subject, depending, for example, on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like.
the desired dosage can be delivered three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.
the desired dosage can be delivered using multiple administrations (e.g ., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).
an effective amount of a compound for administration one or more times a day to a 70 kg adult human may comprise about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000 mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg, about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1 mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about 1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosage form.
the compounds described herein, such as of Formula (I) may be at dosage levels sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, preferably from about 0.1 mg/kg to about 40 mg/kg, preferably from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, and more preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
dose ranges as described herein provide guidance for the administration of provided pharmaceutical compositions to an adult.
the amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.
a compound or composition, as described herein can be administered in combination with one or more additional pharmaceutical agents.
the compounds or compositions can be administered in combination with additional pharmaceutical agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.
additional pharmaceutical agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.
the therapy employed may achieve a desired effect for the same disorder, and/or it may achieve different effects.
the compound or composition can be administered concurrently with, prior to, or subsequent to, one or more additional pharmaceutical agents, which may be useful as, e.g., combination therapies.
Pharmaceutical agents include therapeutically active agents.
Pharmaceutical agents also include prophylactically active agents.
Each additional pharmaceutical agent may be administered at a dose and/or on a time schedule determined for that pharmaceutical agent.
the additional pharmaceutical agents may also be administered together with each other and/or with the compound or composition described herein in a single dose or administered separately in different doses.
the particular combination to employ in a regimen will take into account compatibility of the inventive compound with the additional pharmaceutical agents and/or the desired therapeutic and/or prophylactic effect to be achieved. In general, it is expected that the additional pharmaceutical agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.
Exemplary additional pharmaceutical agents include, but are not limited to, anti-proliferative agents, anti-cancer agents, anti-diabetic agents, anti-inflammatory agents, immunosuppressant agents, and a pain-relieving agent.
Pharmaceutical agents include small organic molecules such as drug compounds (e.g., compounds approved by the U.S.
CFR Code of Federal Regulations
proteins proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells.
CFR Code of Federal Regulations
kits e.g ., pharmaceutical packs.
the inventive kits may be useful for preventing and/or treating a proliferative disease (e.g., cancer (e.g., leukemia, melanoma, multiple myeloma), benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, or autoimmune disease).
the kits provided may comprise an inventive pharmaceutical composition or compound and a container (e.g ., a vial, ampule, bottle, syringe, and/or dispenser package, or other suitable container).
provided kits may optionally further include a second container comprising a pharmaceutical excipient for dilution or suspension of an inventive pharmaceutical composition or compound.
the inventive pharmaceutical composition or compound provided in the container and the second container are combined to form one unit dosage form.
kits including a first container comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, and isotopically labeled derivative, or a pharmaceutical composition thereof.
the kit of the invention includes a first container comprising a compound described herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
the kits are useful in preventing and/or treating a proliferative disease in a subject.
kits further include instructions for administering the compound, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, isotopically and labeled derivative thereof, or a pharmaceutical composition thereof, to a subject to prevent and/or treat a proliferative disease.
the present invention also provides methods for the treatment or prevention of a proliferative disease (e.g ., cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, or autoimmune disease) or an infectious disease (e.g ., a viral disease) in a subject.
a proliferative disease e.g ., cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, or autoimmune disease
infectious disease e.g ., a viral disease
Such methods comprise the step of administering to the subject in need thereof an effective amount of a compound described herein, such as of Formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof, or a pharmaceutical composition thereof.
the methods described herein include administering to a subject an effective amount of a compound described herein, such as of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
a method of treating a subject suffering from a disease or condition associated with aberrant activity of CDK7 comprising the step of administering to the subject in need thereof with a composition described herein, e.g., a composition comprising a compound as described herein, e.g., a compound of formula (I).
the disease or condition is selected from cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, autoimmune disease, or an infectious disease.
the subject is a mammal.
the disease is cancer.
the cancer is selected from a blood cancer, melanoma, a bone cancer, a breast cancer, a brain cancer, or a lung cancer.
the cancer is a blood cancer selected from chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), T-cell acute lymphoblastic leukemia (T-ALL), chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), lymphoma, and multiple myeloma.
the disease is a bone cancer selected from osteosarcoma and Ewing's sarcoma.
the disease is triple-negative breast cancer (TNBC).
the disease is neuroblastoma.
the disease is small cell lung cancer (SCLC).
the method comprises the additional step of administering to the subject in need thereof one or more additional agents independently selected from anti-proliferative agents, anti-cancer agents, immunosuppressant agents, and pain-relieving agents.
the subject being treated is a mammal.
the subject is a human.
the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat.
the subject is a companion animal such as a dog or cat.
the subject is a livestock animal such as a cow, pig, horse, sheep, or goat.
the subject is a zoo animal.
the subject is a research animal such as a rodent, dog, or non-human primate.
the subject is a non-human transgenic animal such as a transgenic mouse or transgenic pig.
the proliferative disease to be treated or prevented using the compounds described herein, such as of Formula (I) will typically be associated with aberrant activity of CDK7.
Aberrant activity of CDK7 may be an elevated and/or an inappropriate (e.g., abnormal) activity of CDK7.
CDK7 is not overexpressed, and the activity of CDK7 is elevated and/or inappropriate.
CDK7 is overexpressed, and the activity of CDK7 is elevated and/or inappropriate.
the compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof, may inhibit the activity of CDK7 and be useful in treating and/or preventing proliferative diseases.
the proliferative disease to be treated or prevented using the compounds described herein, such as of Formula (I), will typically be associated with aberrant activity of CDK12 and/or CDK13.
Aberrant activity of CDK12 and/or CDK13 may be an elevated and/or an inappropriate (e.g., abnormal) activity of CDK12 and/or CDK13.
CDK12 and/or CDK13 is not overexpressed, and the activity of CDK12 and/or CDK13 is elevated and/or inappropriate.
CDK12 and/or CDK13 is overexpressed, and the activity of CDK12 and/or CDK13 is elevated and/or inappropriate.
the compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof, may inhibit the activity of CDK12 and/or CDK13 and be useful in treating and/or preventing proliferative diseases.
a proliferative disease may also be associated with inhibition of apoptosis of a cell in a biological sample or subject. All types of biological samples described herein or known in the art are contemplated as being within the scope of the invention. Inhibition of the activity of CDK7 is expected to cause cytotoxicity via induction of apoptosis.
the compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof, may induce apoptosis, and therefore, be useful in treating and/or preventing proliferative diseases.
the proliferative disease to be treated or prevented using the compounds described herein, such as of Formula (I) is cancer. All types of cancers disclosed herein or known in the art are contemplated as being within the scope of the invention.
the proliferative disease is a cancer associated with dependence on BCL-2 anti-apoptotic proteins (e.g ., MCL-1 and/or XIAP).
the proliferative disease is a cancer associated with overexpression of MYC (a gene that codes for a transcription factor).
the proliferative disease is a hematological malignancy.
the proliferative disease is a blood cancer.
the proliferative disease is leukemia. In certain embodiments, the proliferative disease is chronic lymphocytic leukemia (CLL). In certain embodiments, the proliferative disease is acute lymphoblastic leukemia (ALL). In certain embodiments, the proliferative disease is T-cell acute lymphoblastic leukemia (T-ALL). In certain embodiments, the proliferative disease is chronic myelogenous leukemia (CML). In certain embodiments, the proliferative disease is acute myelogenous leukemia (AML). In certain embodiments, the proliferative disease is lymphoma. In certain embodiments, the proliferative disease is melanoma.
the proliferative disease is multiple myeloma. In certain embodiments, the proliferative disease is a bone cancer. In certain embodiments, the proliferative disease is osteosarcoma. In some embodiments, the proliferative disease is Ewing's sarcoma. In some embodiments, the proliferative disease is triple-negative breast cancer (TNBC). In some embodiments, the proliferative disease is a brain cancer. In some embodiments, the proliferative disease is neuroblastoma. In some embodiments, the proliferative disease is a lung cancer. In some embodiments, the proliferative disease is small cell lung cancer (SCLC). In some embodiments, the proliferative disease is large cell lung cancer. In some embodiments, the proliferative disease is a benign neoplasm. All types of benign neoplasms disclosed herein or known in the art are contemplated as being within the scope of the invention.
the proliferative disease is associated with angiogenesis. All types of angiogenesis disclosed herein or known in the art are contemplated as being within the scope of the invention.
the proliferative disease is an inflammatory disease. All types of inflammatory diseases disclosed herein or known in the art are contemplated as being within the scope of the invention. In certain embodiments, the inflammatory disease is rheumatoid arthritis. In some embodiments, the proliferative disease is an autoinflammatory disease. All types of autoinflammatory diseases disclosed herein or known in the art are contemplated as being within the scope of the invention. In some embodiments, the proliferative disease is an autoimmune disease. All types of autoimmune diseases disclosed herein or known in the art are contemplated as being within the scope of the invention.
the cell described herein may be an abnormal cell.
the cell may be in vitro or in vivo.
the cell is a proliferative cell.
the cell is a blood cell.
the cell is a lymphocyte.
the cell is a cancer cell.
the cell is a leukemia cell.
the cell is a CLL cell.
the cell is a melanoma cell.
the cell is a multiple myeloma cell.
the cell is a benign neoplastic cell.
the cell is an endothelial cell.
the cell is an immune cell.
the present invention provides methods of down-regulating the expression of CDK7 in a biological sample or subject.
the methods described herein comprise the additional step of administering one or more additional pharmaceutical agents in combination with the compound described herein, such as of Formula (I), a pharmaceutically acceptable salt thereof, or compositions comprising such compound or pharmaceutically acceptable salt thereof.
additional pharmaceutical agents include, but are not limited to, anti-proliferative agents, anti-cancer agents, anti-diabetic agents, anti-inflammatory agents, immunosuppressant agents, and a pain-relieving agent.
the additional pharmaceutical agent(s) may synergistically augment inhibition of CDK7 induced by the inventive compounds or compositions of this invention in the biological sample or subject.
the combination of the inventive compounds or compositions and the additional pharmaceutical agent(s) may be useful in treating proliferative diseases resistant to a treatment using the additional pharmaceutical agent(s) without the inventive compounds or compositions.
the present invention provides the compounds described herein, such as of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof, for use in the treatment of a proliferative disease in a subject.
the compounds described herein, and pharmaceutically acceptable salts and compositions thereof, for use in the treatment of a proliferative disease in a subject are provided by the invention are the compounds described herein, and pharmaceutically acceptable salts and compositions thereof, for use in inhibiting cell growth.
provided by the invention are the compounds described herein, and pharmaceutically acceptable salts and compositions thereof, for use in inducing apoptosis in a cell. In certain embodiments, provided by the invention are the compounds described herein, and pharmaceutically acceptable salts and compositions thereof, for use in inhibiting transcription.
protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in Greene et al., Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991 , and references cited therein.
N-(5-(((5-(tert-butyl)oxazol-2-yl)methyl)thio)thiazol-2-yl)piperidine-4-carboxamide 13 mg, 0.0342 mmol was dissolved in dichloromethane (0.7 mL), followed by the addition of triethylamine (0.01 mL, 0.0683 mmol) and by acryloyl chloride (6 ⁇ L, 0.0683 mmol). The reaction was stirred at room temperature for 16 h. At completion, the reaction mixture was poured into sat. NaHCO 3 (5 mL) and extracted with dichloromethane (5 mL x 3). Combined organics were dried over Na 2 SO 4 , filtered and concentrated.
Example 12 1-(1-Acryloylpiperidine-4-carbonyl)-N-(5-(((5-(tert-butyl)oxazol-2-yl)methyl)thio)thiazol-2-yl)piperidine-4-carboxamide (Compound 123)
Example 13 1-(3-Acrylamidobenzoyl)-N-(5-(((5-(tert-butyl)oxazol-2-yl)methyl)thio)thiazol-2-yl)piperidine-4-carboxamide (Compound 124)
reaction mixture was diluted with DCM (20 mL) and washed with water (2 x 20 mL). The combined organic solvents were dried over Na 2 SO 4 . After removal of solvent, the residue was purified by preparative HPLC to afford the title compound (70 mg, yield 31%) as a white solid.
N5-(6-aminohexyl)-N7-benzyl-3-isopropylpyrazolo[1,5-a]pyrimidine-5,7-diamine (6 mg, 0.014 mmol) was dissolved in tetrahydrofuran (2.8 mL), followed by addition of triethylamine (63 ⁇ L, 0.44 mmol) and acryloyl chloride (0.14 ⁇ L, 0.17 mmol). The reaction was stirred at room temperature for 16 h. Upon completion, the reaction mixture was poured into sat. NaHCO 3 (10 mL) and extracted with dichloromethane (10 mL x 3). The combined organics were dried over Na 2 SO 4 , filtered, and concentrated.
Example 18 Inhibition of A637 Cell Proliferation.
Representative compounds of the invention were tested at different concentrations (from 4 ⁇ M to 126.4 pM; 0.5 log serial dilutions) for their ability to inhibit the proliferation of A673 cells.
Known CDK inhibitors flavopiridol and triptolide were used as positive controls.
Cells were grown in Dulbecco's Modified Eagle's Medium, + 10% FBS +1mM Sodium Pyruvate. The cells were cultured at 37 °C in a humidified chamber in the presence of 5% CO 2 . Proliferation assays were conducted over a 72 hour time period.
CyQUANT® (Life Technologies, Chicago, IL USA) was used to assess the anti-proliferative effects of the compounds following manufacturer's directions and utilizing the reagents supplied with the CyQUANT® kit. The results of the assay are shown below in Table 3, where "A” represents an IC 50 of less than 500 nM; "B” an IC 50 of between 500 nM and 5 ⁇ M; and "C” an IC 50 of greater than 5 ⁇ M. Table 3. Inhibition of Proliferation of A673 Cells by Compounds of the Invention. Compound No. A673 IC 50 Compound No. A673 IC 50 Compound No. A673 IC 50 Compound No. A673 IC 50 102 B 118 A 123 A 103 B 119 A 124 A 104 A 120 A 125 A 105 A 121 A 127 A 117 A 122 A
the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, and descriptive terms from one or more of the listed claims is introduced into another claim.
any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim.
elements are presented as lists, e.g., in Markush group format, each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should it be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements and/or features, certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements and/or features.

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP20187913.7A 2014-04-05 2015-04-03 Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) Withdrawn EP3805218A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461975773P	2014-04-05	2014-04-05
PCT/US2015/024336 WO2015154022A1 (fr)	2014-04-05	2015-04-03	Inhibiteurs de kinase cycline-dépendante 7 (cdk7)
EP15718306.2A EP3129371B1 (fr)	2014-04-05	2015-04-03	Inhibiteurs de kinase cycline-dépendante 7 (cdk7)

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
EP15718306.2A Division EP3129371B1 (fr)	2014-04-05	2015-04-03	Inhibiteurs de kinase cycline-dépendante 7 (cdk7)

Publications (1)

Publication Number	Publication Date
EP3805218A1 true EP3805218A1 (fr)	2021-04-14

Family

ID=52998238

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP15718306.2A Not-in-force EP3129371B1 (fr)	2014-04-05	2015-04-03	Inhibiteurs de kinase cycline-dépendante 7 (cdk7)
EP20187913.7A Withdrawn EP3805218A1 (fr)	2014-04-05	2015-04-03	Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP15718306.2A Not-in-force EP3129371B1 (fr)	2014-04-05	2015-04-03	Inhibiteurs de kinase cycline-dépendante 7 (cdk7)

Country Status (4)

Country	Link
US (5)	US10336760B2 (fr)
EP (2)	EP3129371B1 (fr)
AU (4)	AU2015240518A1 (fr)
WO (1)	WO2015154022A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2010343102B2 (en)	2009-12-29	2016-03-24	Dana-Farber Cancer Institute, Inc.	Type II Raf kinase inhibitors
EP2822935B1 (fr)	2011-11-17	2019-05-15	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de la kinase c-jun-terminale (jnk)
US10112927B2 (en)	2012-10-18	2018-10-30	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en)	2012-10-19	2018-06-19	Dana-Farber Cancer Institute, Inc.	Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014063061A1 (fr)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
ES2676734T3 (es)	2013-10-18	2018-07-24	Syros Pharmaceuticals, Inc.	Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
EP3057956B1 (fr)	2013-10-18	2021-05-05	Dana-Farber Cancer Institute, Inc.	Inhibiteurs polycycliques de la kinase cycline-dépendante 7 (cdk7)
CA2944669A1 (fr)	2014-04-04	2015-10-08	Syros Pharmaceuticals, Inc.	Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
US10017477B2 (en)	2014-04-23	2018-07-10	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
WO2015164604A1 (fr)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de janus kinase marqués de manière hydrophobe et utilisations associées
AU2015337607B2 (en)	2014-10-31	2020-04-09	Ube Corporation	Substituted dihydropyrrolopyrazole compound
US10870651B2 (en)	2014-12-23	2020-12-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2978170C (fr) *	2015-03-09	2024-02-27	Aurigene Discovery Technologies Limited	Derives de pyrazolo[1,5-a][1,3,5]triazine et de pyrazolo[1,5-a]pyrimidine utilises en tant qu'inhibiteurs de cdk
EP3268360B1 (fr)	2015-03-09	2019-04-24	Bristol-Myers Squibb Company	Lactames utilisés en tant qu'inhibiteurs de rho-kinases (rock)
AU2016243529B2 (en)	2015-03-27	2021-03-25	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
MY198769A (en)	2015-06-04	2023-09-25	Aurigene Oncology Ltd	Substituted heterocyclic derivatives as cdk inhibitors
US10702527B2 (en)	2015-06-12	2020-07-07	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
JP6787314B2 (ja)	2015-06-15	2020-11-18	宇部興産株式会社	置換ジヒドロピロロピラゾール誘導体
JP7028766B2 (ja) *	2015-09-09	2022-03-02	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼの阻害剤
CN109153675B (zh) *	2016-04-22	2023-05-02	达纳－法伯癌症研究所公司	细胞周期蛋白依赖性激酶9通过cdk9抑制剂与e3连接酶配体的缀合的降解及使用方法
US20200155526A1 (en)	2017-05-31	2020-05-21	The Children's Medical Center Corporation	Targeting lysine demethylases (kdms) as a therapeutic strategy for diffuse large b-cell lymphoma
US10913983B2 (en)	2017-07-18	2021-02-09	University Of South Carolina	Sensitivity markers and uses for CDK7 inhibitors in breast cancers
CN107383019B (zh) *	2017-07-28	2019-10-15	江苏艾凡生物医药有限公司	吡唑并[4,3-h]喹唑啉类化合物及其用途
US11046698B2 (en)	2017-07-28	2021-06-29	Nimbus Lakshmi, Inc.	TYK2 inhibitors and uses thereof
TWI703149B (zh) *	2017-11-16	2020-09-01	美商美國禮來大藥廠	用於抑制cdk7之化合物
CA3095426A1 (fr) *	2018-04-11	2019-10-17	Qurient Co., Ltd.	Derives de pyrazolotriazine et/ou de pyrazolopyrimidine pharmaceutiquement actifs
CN112313235A (zh) *	2018-04-11	2021-02-02	奎利恩特有限公司	作为周期蛋白依赖性激酶的选择性抑制剂的吡唑并-三嗪和/或吡唑并-嘧啶衍生物
AU2019295632B2 (en)	2018-06-25	2025-03-06	Dana-Farber Cancer Institute, Inc.	Taire family kinase inhibitors and uses thereof
EA039950B1 (ru) *	2018-07-20	2022-03-31	Эли Лилли Энд Компани	Соединения, пригодные для ингибирования cdk7
CN110835345A (zh) *	2018-08-17	2020-02-25	中国科学院上海药物研究所	一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
TWI767148B (zh)	2018-10-10	2022-06-11	美商弗瑪治療公司	抑制脂肪酸合成酶(fasn)
AU2019370200B2 (en)	2018-10-30	2024-12-19	Kronos Bio, Inc.	Compounds, compositions, and methods for modulating CDK9 activity
US20210401859A1 (en) *	2018-11-01	2021-12-30	Syros Pharmaceuticals, Inc.	Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020100944A1 (fr)	2018-11-14	2020-05-22	宇部興産株式会社	Dérivé de dihydropyrrolopyrazole
US11034669B2 (en)	2018-11-30	2021-06-15	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
JP7660063B2 (ja)	2018-12-28	2025-04-10	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
CN113004285B (zh) *	2019-12-20	2024-05-14	苏州信诺维医药科技股份有限公司	杂环化合物及其药物组合物、制备方法、中间体和应用
TWI783480B (zh)	2020-05-27	2022-11-11	美商美國禮來大藥廠	用於抑制cdk7之化合物
CN114133394B (zh) *	2020-08-12	2023-12-08	赛诺哈勃药业（成都）有限公司	一种选择性针对细胞周期依赖性激酶12活性的化合物、制备方法及医药用途
US12084453B2 (en)	2021-12-10	2024-09-10	Incyte Corporation	Bicyclic amines as CDK12 inhibitors
WO2023227125A1 (fr) *	2022-05-26	2023-11-30	杭州德睿智药科技有限公司	Nouveau composé hétérocyclique fusionné en tant qu'inhibiteur de cdk et son utilisation
AU2023398977A1 (en) *	2022-12-13	2025-06-19	Wavebreak Therapeutics, Llc	Compounds, compositions, and methods of treating disorders associated with protein misfolding
WO2025040170A1 (fr) *	2023-08-24	2025-02-27	杭州德睿智药科技有限公司	Nouveau composé hétérocyclique condensé servant d'inhibiteur de cdk et son utilisation

Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5571813A (en) *	1993-06-10	1996-11-05	Beiersdorf-Lilly Gmbh	Fused pyrimidine compounds and their use as pharmaceuticals
EP1262828A1 (fr) *	2001-06-01	2002-12-04	Fuji Photo Film Co., Ltd.	Matériau d'enregistrement
WO2004022561A1 (fr) *	2002-09-04	2004-03-18	Schering Corporation	Pyrazolopyrimidines tenant lieu d'inhibiteurs de kinases dependantes de la cycline
WO2004076458A1 (fr) *	2003-02-28	2004-09-10	Teijin Pharma Limited	Derives de pyrazolo[1,5-a]pyrimidine
WO2004081013A1 (fr) *	2003-03-11	2004-09-23	Teijin Pharma Limited	Inhibiteurs de proteine kinase
WO2008151304A1 (fr) *	2007-06-05	2008-12-11	Emory University	Inhibiteurs sélectifs des kinases cycline-dépendantes
WO2013074986A1 (fr) *	2011-11-17	2013-05-23	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de la kinase c-jun-n-terminale (jnk)
WO2013128028A1 (fr) *	2012-03-01	2013-09-06	Lead Discovery Center Gmbh	Dérivés pyrazolo-triazine utiles en tant qu'inhibiteurs des kinases dépendant des cyclines
WO2013128029A1 (fr) *	2012-03-01	2013-09-06	Lead Discovery Center Gmbh	Dérivés pyrazolo-triazine pharmaceutiquement actifs
WO2016142855A2 (fr) *	2015-03-09	2016-09-15	Aurigene Discovery Technologies Limited	Dérivés de pyrazolo[1,5-a][1,3,5]triazine et de pyrazolo[1,5-a]pyrimidine utilisés en tant qu'inhibiteurs de cdk

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2389126A (en) *	1944-06-13	1945-11-20	Parke Davis & Co	Therapeutically useful sulphones and their preparation
US6262096B1 (en) *	1997-11-12	2001-07-17	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
US6515004B1 (en) *	1999-12-15	2003-02-04	Bristol-Myers Squibb Company	N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
DK1347971T3 (da) *	2000-12-21	2006-05-15	Bristol Myers Squibb Co	Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
WO2008033747A2 (fr) *	2006-09-11	2008-03-20	Curis, Inc.	Petites molécules multifonctionnelles servant d'agents anti-prolifératifs
WO2008079873A2 (fr) *	2006-12-20	2008-07-03	Bristol-Myers Squibb Company	Utilisation de composés thiazolyle comme inhibiteurs de kinases
CN101679406B (zh) *	2007-04-10	2013-07-10	百时美施贵宝公司	用作激酶抑制剂的噻唑基化合物
TW200922564A (en) *	2007-09-10	2009-06-01	Curis Inc	CDK inhibitors containing a zinc binding moiety
WO2010075542A1 (fr) *	2008-12-23	2010-07-01	Curis, Inc.	Inhibiteurs de cdk
ES2744597T3 (es) *	2012-03-28	2020-02-25	Intervet Int Bv	Compuestos de heteroarilo con una unidad acíclica como puente
US10870651B2 (en) *	2014-12-23	2020-12-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
TWI703149B (zh) *	2017-11-16	2020-09-01	美商美國禮來大藥廠	用於抑制cdk7之化合物

2015
- 2015-04-03 EP EP15718306.2A patent/EP3129371B1/fr not_active Not-in-force
- 2015-04-03 WO PCT/US2015/024336 patent/WO2015154022A1/fr not_active Ceased
- 2015-04-03 EP EP20187913.7A patent/EP3805218A1/fr not_active Withdrawn
- 2015-04-03 AU AU2015240518A patent/AU2015240518A1/en not_active Abandoned
- 2015-04-03 US US15/301,819 patent/US10336760B2/en active Active
2019
- 2019-05-15 US US16/412,721 patent/US20190330218A1/en not_active Abandoned
- 2019-07-17 US US16/513,912 patent/US20200010473A1/en not_active Abandoned
- 2019-08-28 AU AU2019222848A patent/AU2019222848A1/en not_active Abandoned
2020
- 2020-09-18 US US17/025,168 patent/US20210221814A1/en not_active Abandoned
- 2020-12-14 US US17/121,191 patent/US20210107912A1/en not_active Abandoned
2021
- 2021-03-10 AU AU2021201536A patent/AU2021201536A1/en not_active Abandoned
- 2021-05-13 AU AU2021203051A patent/AU2021203051A1/en not_active Abandoned

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5571813A (en) *	1993-06-10	1996-11-05	Beiersdorf-Lilly Gmbh	Fused pyrimidine compounds and their use as pharmaceuticals
EP1262828A1 (fr) *	2001-06-01	2002-12-04	Fuji Photo Film Co., Ltd.	Matériau d'enregistrement
WO2004022561A1 (fr) *	2002-09-04	2004-03-18	Schering Corporation	Pyrazolopyrimidines tenant lieu d'inhibiteurs de kinases dependantes de la cycline
WO2004076458A1 (fr) *	2003-02-28	2004-09-10	Teijin Pharma Limited	Derives de pyrazolo[1,5-a]pyrimidine
WO2004081013A1 (fr) *	2003-03-11	2004-09-23	Teijin Pharma Limited	Inhibiteurs de proteine kinase
WO2008151304A1 (fr) *	2007-06-05	2008-12-11	Emory University	Inhibiteurs sélectifs des kinases cycline-dépendantes
WO2013074986A1 (fr) *	2011-11-17	2013-05-23	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de la kinase c-jun-n-terminale (jnk)
WO2013128028A1 (fr) *	2012-03-01	2013-09-06	Lead Discovery Center Gmbh	Dérivés pyrazolo-triazine utiles en tant qu'inhibiteurs des kinases dépendant des cyclines
WO2013128029A1 (fr) *	2012-03-01	2013-09-06	Lead Discovery Center Gmbh	Dérivés pyrazolo-triazine pharmaceutiquement actifs
WO2016142855A2 (fr) *	2015-03-09	2016-09-15	Aurigene Discovery Technologies Limited	Dérivés de pyrazolo[1,5-a][1,3,5]triazine et de pyrazolo[1,5-a]pyrimidine utilisés en tant qu'inhibiteurs de cdk

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BERGE ET AL.: "describe pharmaceutically acceptable salts in detail", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
CARRUTHERS: "Some Modern Methods of Organic Synthesis", 1987, CAMBRIDGE UNIVERSITY PRESS
DATABASE PubChem Compound [online] NCBI; 1 December 2013 (2013-12-01), XP002740370, Database accession no. CID 71994675 *
ELIEL, E.L.: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL
GREENE ET AL.: "Protecting Groups in Organic Synthesis", 1991, WILEY
JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE
LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS, INC.
SHIOTA T ET AL: "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF A NEW SERIES OF POTENT ANGIOTENSIN II RECEPTOR ANTAGONISTS: PYRAZOLOÄ1,5-AÜPYRIMIDINE DERIVATIVES", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 47, no. 7, 1 January 1999 (1999-01-01), pages 928 - 938, XP001156827, ISSN: 0009-2363 *
SMITHMARCH: "March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS, INC.
THOMAS SORRELL: "Handbook of Chemistry and Physics", 1999, UNIVERSITY SCIENCE BOOKS
WALKER: "Cambridge Dictionary of Biology", 1990, CAMBRIDGE UNIVERSITY PRESS
WILEN ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725
WILEN, S.H.: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268

Also Published As

Publication number	Publication date
US20210107912A1 (en)	2021-04-15
AU2021203051A1 (en)	2021-06-10
AU2015240518A1 (en)	2016-10-20
EP3129371B1 (fr)	2020-07-29
AU2021201536A1 (en)	2021-03-25
EP3129371A1 (fr)	2017-02-15
AU2019222848A1 (en)	2019-09-19
US20200010473A1 (en)	2020-01-09
WO2015154022A1 (fr)	2015-10-08
US20170174692A1 (en)	2017-06-22
US10336760B2 (en)	2019-07-02
US20210221814A1 (en)	2021-07-22
US20190330218A1 (en)	2019-10-31

Publication	Publication Date	Title
EP3129371B1 (fr)	2020-07-29	Inhibiteurs de kinase cycline-dépendante 7 (cdk7)
US11040957B2 (en)	2021-06-22	Heteroaromatic compounds useful for the treatment of proliferative diseases
US10865206B2 (en)	2020-12-15	Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3126352B1 (fr)	2018-10-17	Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
US20190292167A1 (en)	2019-09-26	Heteroaromatic compounds useful for the treatment of proliferative diseases
WO2016196910A1 (fr)	2016-12-08	Composés pour la modulation de l'activité de myc
US20210221820A1 (en)	2021-07-22	Compounds for the modulation of myc activity
HK1229328A1 (en)	2017-11-17	Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK1229328B (en)	2019-10-11	Inhibitors of cyclin-dependent kinase 7 (cdk7)

Legal Events

Date	Code	Title	Description
2021-03-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-03-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED
2021-04-14	AC	Divisional application: reference to earlier application	Ref document number: 3129371 Country of ref document: EP Kind code of ref document: P
2021-04-14	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-10-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-11-24	17P	Request for examination filed	Effective date: 20211014
2021-11-24	RBV	Designated contracting states (corrected)	Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-12-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-01-18	17Q	First examination report despatched	Effective date: 20221214
2023-08-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2023-09-27	18D	Application deemed to be withdrawn	Effective date: 20230425